Sylvie Laquerre
20Patents
5h-index
46Co-inventors
69Inventor score
Filing activity: Dec 8, 2000 → Jul 29, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6723316B2 | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth | Chemistry; Metallurgy | 34 | Expired |
| US8703781B2 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Human Necessities | 12 | Active |
| US8952018B2 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Human Necessities | 10 | Active |
| US7078030B2 | Oncolytic adenovirus | Chemistry; Metallurgy | 10 | Expired |
| US10869869B2 | Method of adjuvant cancer treatment | Human Necessities | 8 | Active |
| US7396679B2 | Oncolytic adenovirus | Chemistry; Metallurgy | 3 | Expired |
| US8642596B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | Emerging Cross-Sectional Technologies | 2 | Active |
| US6660259B2 | Herpes simplex virus for treating unwanted hyperproliferative cell growth | Chemistry; Metallurgy | 1 | Expired |
| US12215160B2 | Treatment of patients having c-met exon 14 skipping mutations | Physics | 0 | Active |
| US11879013B2 | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US8835450B2 | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer | Human Necessities | 0 | Active |
| US9402846B2 | Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer | Human Necessities | 0 | Active |
| US11827708B2 | Proteins comprising HLA-G antigen binding domains and their uses | Chemistry; Metallurgy | 0 | Active |
| US7414113B2 | Antibody that specifically binds to Candida kefyr Cytosine deaminase | Emerging Cross-Sectional Technologies | 0 | Active |
| US8796298B2 | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer | Human Necessities | 0 | Active |
| US11472830B2 | Cyclic dinucleotides as sting agonists | Human Necessities | 0 | Active |
| US7556955B2 | Nucleic acids encoding Candida kefyr cytosine deaminase | Emerging Cross-Sectional Technologies | 0 | Active |
| US7141404B2 | Candida kefyr cytosine deaminase | Emerging Cross-Sectional Technologies | 0 | Expired |
| US8962667B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Chemistry; Metallurgy | 0 | Active |
| US9067873B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.